References
- Boyd E JS, Wood J R. H2-receptor antagonists in the treatment of reflux oesophagitis. Scand J Gastroenterol 1989; 24(suppl 171)136–143
- Festen H PM. Profound gastric acid inhibition: advantages and potential hazards. Scand J Gastroenterol 1989; 24(suppl 171)99–105
- Jansen E H, Horbach J MLM, Klamer M, Jansen J BMJ, Hopman W PM, Gooszen H G, Lamers C BHW. Plasma pancreatic polypeptide responses to insulin hypoglycaemia after Nissen fundop-lication. Scand J Gastroenterol 1989; 24(suppl 171)9–12
- Meuwissen S GM, Klinkenberg-Knol E C. Treatment of reflux oesophagitis with H2-receptor antagonists. Scand J Gastroenterol 1988; 23(suppl 146)201–212
- Lamers C BHW, Jansen J BMJ. Improved efficacy of histamine H2-receptor antagonists. Actualities in hepatogastroenterology, G NJ Tijtgat. G. Thieme, Stuttgart 1989, in press
- Tijtgat G NJ, Nio C Y. The medical treatment of reflux oesophagitis. Clin Gastroenterol 1987; 1: 791–807
- Jansen J BMJ, Lamers C BHW. Medical treatment of reflux oesophagitis. J Drug Ther Res 1989; 14: 45–49
- Masci E, Testoni P A, Passaretti S, Guslandi M, Tittobello A. Comparison of ranitidine, dom-peridone maleate and ranitidine plus domperidone maleate in the short-term treatment of reflux oesophagitis. Drug Exp Clin Res 1985; 11: 687–692
- Wienbeck M. Therapeutic effect of cisapride added on to ranitidine in patients with reflux esophagitis. Dig Dis Sci 1986; 31: 27S
- Galmiche J P, Brandstatter G, Evreux M, et al. Combined therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind controlled trial. Gut 1988; 29: 675–681
- Herrera J L, Shay S S, McCabe M, Peura D A, Johnson L F. Sucralfate used as adjunctive therapy in patients with severe erosive peptic esophagitis. Gastroenterology 1989; 96: A207
- Hameeteman W, Scotborgh R H, van de Boomgaard D M, et al. Combination therapy of sucralfate and cimetidine compared with sucralfate monotherapy in patients with reflux oesophagitis. Z Gastroenterol 1989; 27: 137–139
- Robertson D AF, Aldersley M A, Shepherd H, Lloyd R S, Smith C L. H2 antagonists in the treatment of reflux oesophagitis: can physiological studies predict the response?. Gut 1987; 28: 946–949
- Ayres R CS, Ryan L, Robertson D AF, Smith C L. Treatment failure with H2-receptor antagonists in reflux oesophagitis is due to diminished suppression of gastric acid secretion. Gastroenterology 1989; 96: A20
- Jansen J BMJ, Lamers C BHW. Omeprazole in the short-term treatment of reflux oesophagitis. Digestion 1989; 44(suppl 1)40–46
- Klinkenberg-Knol E C, Jansen J BMJ, Lamers C BHW, Nelis F, Snel P, Meuwissen S GM. Use of omeprazole in the management of reflux oesophagitis resistant to H2-receptor antagonist. Scand J Gastroenterol 1989; 24(suppl 166)88–93
- Collen M J, Howard J M, McArthur K, et al. Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion. Ann Intern Med 1984; 100: 52–58
- Jansen J BMJ, Baak L C, Lamers C BHW. Effect of increasing doses of ranitidine on exposure of the oesophagus to gastric acid in patients with reflux oesophagitis. Scand J Gastroenterol 1988; 23(suppl 154)2–5
- Johnson N J, Boyd E JS, Mills J G, Wood J R. Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s. Aliment Pharmacol Ther 1989; 3: 259–266